南模生物
(688265)
| 流通市值：31.12亿 | | | 总市值：31.12亿 |
| 流通股本：7796.35万 | | | 总股本：7796.35万 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 232,436,961.68 | 99,917,106.36 | 421,024,337.24 | 302,700,815.36 |
| 营业总成本 | 229,620,819.95 | 101,847,429.13 | 406,371,770.42 | 285,426,118.09 |
| 其他经营收益 | | | | |
| 营业利润 | 7,912,517.12 | 453,779.58 | 29,988,075.25 | 26,555,831.65 |
| 利润总额 | 7,854,648.12 | 395,910.58 | 29,101,130.55 | 25,724,788.94 |
| 净利润 | 9,076,619.83 | 683,635.56 | 31,436,529.76 | 26,764,905.11 |
| 每股收益 | | | | |
| 其他综合收益 | -95,881.77 | 17,200.94 | -277,676.1 | -155,144.81 |
| 综合收益总额 | 8,980,738.06 | 700,836.5 | 31,158,853.66 | 26,609,760.3 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 1,118,634,679.33 | 1,110,568,118.9 | 1,181,236,122.81 | 1,150,468,543.88 |
| 非流动资产: | | | | |
| 非流动资产合计 | 877,182,065.41 | 855,174,399.84 | 802,286,932.72 | 748,745,995.32 |
| 资产总计 | 1,995,816,744.74 | 1,965,742,518.74 | 1,983,523,055.53 | 1,899,214,539.2 |
| 流动负债: | | | | |
| 流动负债合计 | 221,917,173.5 | 190,357,795.36 | 215,968,746.89 | 154,045,047.57 |
| 非流动负债: | | | | |
| 非流动负债合计 | 56,266,991.6 | 62,631,312.31 | 58,365,998.37 | 43,079,496.78 |
| 负债合计 | 278,184,165.1 | 252,989,107.67 | 274,334,745.26 | 197,124,544.35 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,717,632,579.64 | 1,712,753,411.07 | 1,709,188,310.27 | 1,702,089,994.85 |
| 股东权益合计 | 1,717,632,579.64 | 1,712,753,411.07 | 1,709,188,310.27 | 1,702,089,994.85 |
| 负债和股东权益合计 | 1,995,816,744.74 | 1,965,742,518.74 | 1,983,523,055.53 | 1,899,214,539.2 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 176,953,404.38 | 80,094,495.09 | 441,995,639.04 | 283,031,576.85 |
| 经营活动现金流出小计 | 217,803,648.13 | 115,472,445.65 | 345,076,392.47 | 263,390,493.89 |
| 经营活动产生的现金流量净额 | -40,850,243.75 | -35,377,950.56 | 96,919,246.57 | 19,641,082.96 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,051,506,402.44 | 659,137,588.88 | 2,964,820,796.81 | 2,351,249,376.76 |
| 投资活动现金流出小计 | 967,807,570.68 | 450,405,297.58 | 3,090,011,357.46 | 2,432,721,909.64 |
| 投资活动产生的现金流量净额 | 83,698,831.76 | 208,732,291.3 | -125,190,560.65 | -81,472,532.88 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 4,204,886.4 | - | - | - |
| 筹资活动现金流出小计 | 9,833,077.48 | 3,645,586.16 | 20,406,417.32 | 14,702,993.05 |
| 筹资活动产生的现金流量净额 | -5,628,191.08 | -3,645,586.16 | -20,406,417.32 | -14,702,993.05 |
| 汇率变动对现金及现金等价物的影响 | -2,577,098.86 | -1,314,584.34 | -1,747,828.67 | -672,617.2 |
| 现金及现金等价物净增加额 | 34,643,298.07 | 168,394,170.24 | -50,425,560.07 | -77,207,060.17 |
| 期末现金及现金等价物余额 | 180,432,583.6 | 314,256,118.17 | 145,789,285.53 | 119,007,785.43 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 34,643,298.07 | - | -50,425,560.07 | - |